Plexxikon Inc. Announces Three-Year Survival in Zelboraf-Treated Metastatic Melanoma Patients

Published: Nov 09, 2012

BERKELEY, Calif. & LOS ANGELES--(BUSINESS WIRE)--Plexxikon today announced that updated Phase 1 clinical data of Zelboraf® (vemurafenib) were presented at the Society for Melanoma Research (SMR) 2012 Congress, held November 8-11 in Los Angeles, CA. These data represent the longest follow-up of any cohort of patients treated with any BRAF inhibitor. The data show that 26 percent of patients were alive at three years suggesting that long-term survival with Zelboraf can be achieved in a subset of metastatic melanoma patients with the BRAF V600E mutation. The Phase 1 extension study, which was conducted by Plexxikon and Plexxikon’s partner Roche, included 32 patients with BRAF V600E mutation-positive melanoma.

Back to news